Adoptive T Cell Immunotherapy for Advanced Melanoma
This study is testing a new treatment for advanced melanoma called autologous bulk TIL 13831 TCR transduced T cells. This treatment uses your own immune cells (T cells) that have been specially modified to fight cancer. The main goal of this Phase 1 study is to find the highest dose of these modified T cells that can be given safely. Researchers will be looking for any serious side effects (Grade 2 through Grade 5 Adverse Events) related to the treatment within 4 weeks. You may be able to join if you are 18 years or older and have metastatic melanoma, which means your cancer has spread. This study plans to enroll about 18 patients.
- Study design
- This is a Phase 1 dose-escalation study, meaning different groups of patients will receive increasing doses of the treatment. It plans to enroll about 18 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored clinically and immunologically for a year after the infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT02870244
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Recruiting
PHASE1Ages 18–89InterventionalTreatmentLoyola UniversityInvestigator-initiated
~18 participants
Updated 2018-03-12 on ClinicalTrials.gov
What's tested:Escalating Doses
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Approximately 18 patients with Grade 2 through Grade 5 Adverse Events that are related to study drug, graded according to NCI CTCAE Version 4.0
Measured over 4 weeks
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Michael Nishimura, PhD · PRINCIPAL_INVESTIGATOR · Loyola University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients must have a diagnosis of metastatic melanoma which is evaluable either clinically or radiologically.
Patients must be 18 years of age or older.
Patients must consent to be in the study and must have signed and dated an approved consent form, which conforms to federal and institutional guidelines.
Patients must have a performance status (PS) of 0 or 1 ECOG PS scale.
Patients must have the ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time.
Patients melanoma must be positive for both tyrosinase and HLA-A2 pathologic review from FNA, core or excisional biopsy of lesion.
Cardiac ejection fraction greater than 50 percent as determined by screening echocardiogram.
Patients that have undergone treatment with anti-CTLA-4, Cytotoxic T-Lymphocyte Antigen 4, antibody must have at least 6 weeks from last dose of CTLA-4 antibody and evidence of tumor progression before they can be enrolled into this study.
Patients that have undergone treatment with anti-PD-1, Programmed Death Receptor 1, Blockade or anti-PD-L1 antibody must have at least 4 weeks from last dose of antibody and evidence of tumor progression before they can be treated in this study.
Patients with V600E mutations are eligible if they have failed an approved BRAF inhibitor or MEK inhibitor therapy or have refused treatment with an approved BRAF inhibitor or MEK inhibitor.
Patients treated with prior Interleukin-2 (IL-2) are eligible.
Sufficient cardiopulmonary reserve for IL-2 per institutional guidelines.
Exclusion
Special classes of subjects such as fetuses, pregnant women, children, prisoners, institutionalized individuals, or others who are likely to be vulnerable.
ECOG performance status of 2 or greater.
Patients with a history metastatic melanoma involving the brain will be excluded if they have active disease or have had active disease within the prior three months that was not controlled with surgery or radiotherapy.
Patients taking steroids for disease control or pain management
Patients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus. Women or men of reproductive potential must have agreed to use an effective contraceptive method.
Patients whose BRAF V600 mutation status is unknown should undergo an attempt to determine this information, patients who have a BRAF V600 mutation and are responding to BRAF with or without MEK inhibitor therapy, or have a BRAF V600 mutation and have not been offered the option of receiving BRAF with or without MEK inhibitor therapy for the treatment of their melanoma are excluded.
No prior malignancy is allowed except for the following- adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years.
Patients that have undergone immunotherapy targeting tyrosinase.
Patients that have undergone immunotherapy in combination with non-myeloablative chemotherapy.
Any of the following abnormal laboratory values Absolute neutrophil count less than 1.5 x 10\^9/L Platelet count less than 100 x 10\^9/L Serum bilirubin greater than 1.5 x upper limit of normal ULN Serum ALT, AST greater than 2.5 x ULN Serum ALP greater than 2 x ULN Serum Albumin less than 2.5 g dL International Normalized Ratio, INR greater than 1.5 Serum creatinine calculated creatinine clearance by the method of Cockcroft and Gault, less than 50mL min.
Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics.
Any severe or poorly controlled systemic disease, for example hypertension, clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound-healing, ulcer or bone fracture.
Patients who have received any chemotherapy or investigational treatment within 4 weeks of study start.
Known infection with HIV, HBV, or HCV.
Known hypersensitivity to any of the components of the study drugs.
Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
What this trial measures
- Approximately 18 patients with Grade 2 through Grade 5 Adverse Events that are related to study drug, graded according to NCI CTCAE Version 4.04 weeks
Establish a recommended phase II dose of autologous T cell receptor transduced T cells by evaluating unexpected Grade 2 adverse events through Grade 5 regardless of attribution, all toxicities attributed to the cells, and all incidences of intubation including the duration and reason for intubation.